The “tissue culture technology” developed in the 19th century has greatly advanced to the “cell culture technology” in which cells are cultured in vitro in the 20th century. This cell culture technology has greatly contributed to research on cancer diseases and viral infections, and has become a new technology for the development of various vaccines.
In the 21st century, pluripotent cells such as ES and iPS cells that differentiate into various cell lineages were created, and the potential of “regenerative medicine” to treat incurable diseases was expanded by these cells. With the development of regenerative medicine, the cell culture media required for in vitro cell culture has become a very important basic material for safe regenerative cell therapy.
We will continue to develop high-performance cell culture media using know-how gained from research and development of cell culture media over many years, and contribute to the development of regenerative cell medicine and biopharmaceuticals.
CEO/President Takeshi Sato
- Executive Chairman TOKUDA MASANORI
（Honorary Professor Tohoku University）
CEO SATO TAKESHI
- Head Office
- 82-16,Imozawa Gongenmoriyama, Aoba-ku, Sendai
- 10 million JPY
- April 10,2015
- 9 (as of May 2019)
- Mizuho Bank, Ltd
Morinomiyako Shinkin Bank